Fig. 3.

Change from baseline in (a) prednisone use and (b) CDAI score at the 6-month follow-up visit in patients with RA who initiated TCZ. ^aIncludes only those patients with a 6-month (± 3 months) follow-up visit with prednisone dose information available; comparisons between subgroups are descriptive in nature. ^bIncludes patients with change in dose of < 5 mg. CDAI Clinical Disease Activity Index, csDMARD conventional synthetic disease-modifying antirheumatic drug, N/A not applicable, RA rheumatoid arthritis, TCZ tocilizumab